IRAK4 and myelodysplastic syndrome: Treatment with IRAK4 inhibitor led to decrease in MDS cells after 3–4 weeks of treatment in five distinct samples (Figure 5B–D, Figure 5—figure supplement 1, Supplementary file 1).